3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
33
Colorectal Neoplasms
12
Neoplasms
11
Pain, Postoperative
10
Lung Neoplasms
9
Brain Neoplasms
8
Stomach Neoplasms
7
Prostatic Neoplasms
7
Pancreatic Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Melanoma
6
Leukemia, Myeloid, Acute
5
Ovarian Neoplasms
4
Myoma
4
Lymphoma, Non-Hodgkin
4
Leiomyoma
4
Hemorrhage
4
Head and Neck Neoplasms
4
Glioblastoma
4
Colonic Neoplasms
4
Agnosia
4
Skin Neoplasms
3
Recurrence
3
Rectal Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neurotoxicity Syndromes
3
Neoplasm Metastasis
3
Nasopharyngeal Carcinoma
3
Myelodysplastic Syndromes
3
Multiple Endocrine Neoplasia Type 1
3
Interventions
Cisplatin
7
Radiotherapy
3
Paclitaxel
3
Carboplatin
3
Brachytherapy
2
zimberelimab
1
piperine
1
pembrolizumab
1
durvalumab
1
camrelizumab
1
atezolizumab
1
Sodium Chloride
1
Neoadjuvant Therapy
1
Gemcitabine
1
Drug Therapy
1
Curcumin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Locally Advanced Cervical Cancer
×
Sodium Chloride
×
Clear all
NCT06079671
2026-05-27
eVOLVECervical
AstraZeneca
Phase 3
Recruiting
800 enrolled